Please ensure Javascript is enabled for purposes of website accessibility

3 Healthcare Stocks Billionaires Love Right Now

You’re reading a free article with opinions that may differ from The Motley Fool’s Premium Investing Services. Become a Motley Fool member today to get instant access to our top analyst recommendations, in-depth research, investing resources, and more. Learn More

Billionaire investors are piling into these three healthcare stocks. Is it a smart idea to follow their move, or should you keep away?

Source: BILL BROOKS, FLICKR CREATIVE COMMONS.

13F reports are filed with the Securities and Exchange Commission by billionaire investors each quarter and make it easy for anyone to track their trades and see what they've been buying and selling recently.  While blindly mimicking each one of their moves is generally a bad idea, those 13Fs can be great place to go hunting for new investment ideas.

Knowing that, we asked our team of contributors to highlight a healthcare stock that a billionaire investor has been buying recently. Following is a list of three stocks that these ultra-rich investors have taken a position in, and some thoughts on whether you might want to follow their move.

Brian Feroldi: Famed billionaire value investor Seth Klarman has really taken a liking to small-cap pharmaceutical company Keryx Pharmaceuticals (KERX). His investment firm, the Baupost Group, recently invested $125 million into the company through a zero-coupon convertible note offering. 

That move is quite a vote of confidence for Keryx. Before the bond offering, the Baupost Group already owned about 25% of Keryx's outstanding shares, making Baupost the company's largest shareholder. So what do Klarman & Co. know about Keryx that has turned them so bullish?

Keryx is a one-drug company whose fate rests in the future success of Auryxia, which is designed to help patients with chronic kidney disease on dialysis better control their serum phosphorus levels. There are roughly 450,000 Americans that fit the profile, and peak annual sales estimates for the drug are running as high as $1 billion in the U.S. alone.

However, sales of Auryxia have been sluggish out of the gate, which management was quick to blame on the drug's poor formulary coverage. A handful of disappointing quarterly results took its toll on shares in 2015:

KERX Chart

Despite the slow start, Klarman's group hasn't sold at all, and the bond deal may help turn around Auryxia's fate. It has already given Klarman's group a handful of board seats, which Klarman has used to put pressure on management to beef up the sales force and lower costs to turn the company's fortunes around.

In recent news, Keryx has won regulatory approval in Europe for Auryxia, and it recently posted solid data from a phase 3 trial that could expand Auryxia's addressable market in the United States. It's also made huge strides to improve access to the drug, so the company is primed for growth in 2016.

Still, while Klarman's investment in Keryx's stock is a big boost of confidence for the company, there's still a lot of risk here, so I'd recommend caution before you blindly follow him into Keryx.

Cory Renauer: When two billionaire investors -- who also happen to be best-selling investment book authors -- show significant interest in a healthcare stock, it's time for a closer look.

Billionaires Ken Fisher and Joel Greenblatt are big fans of Merck & Co. (MRK 1.58%) Philip Fisher's Common Stocks and Uncommon Profits is arguably the most important investment book ever published, but it's not exactly a page-turner. However, his son has made a career of expanding his father's wisdom into a more digestible format.

One of the Fisher family maxims is that talented management is an often underappreciated asset. In 2013, Merck brought on Amgen's former R&D head, Roger Perlmutter. As president of Merck Research Laboratories, Perlmutter expertly shepherded immuno-oncology groundbreaker Keytruda through the regulatory process, winning approval ahead of another drug in the same class, Opdivo from Bristol-Myers Squibb

Although Keytruda is underperforming Opdivo in terms of sales at the moment, looking ahead Merck is building an immuno-oncology juggernaut around Keytruda, with over 200 clinical trials involving more than 100 combinations under way. Perhaps confidence that Perlmutter will deliver in the years ahead is why Fisher has such a large stake in Merck. 

MRK PEG Ratio (Forward) Chart

As for value guru Greenblatt, I think he sees growth at a very reasonable price. At 36 times trailing earnings, Merck hardly seems like a value, but it has one of the lowest forward PEG ratios in the industry, with PEG measured as the forward P/E ratio divided by the expected earnings-per-share growth percentage during the period. Stocks with forward PEG ratios below 1.0 are widely considered undervalued. At just 0.1, Merck shows why it's no wonder Greenblatt loves the stock.

Keith Speights: David Einhorn hasn't always picked winners. His Greenlight Capital fund closed out 2015 down 20%. But one stock the billionaire should feel pretty good about is Mylan (MYL). Greenlight Capital bought 2.89 million shares of the pharmaceutical in late 2015.

Mylan has endured some rough times over the past year. Its rejection of a takeover bid from Teva Pharmaceutical caused shares to tank. Mylan later lost in its own attempt to buy out Perrigo -- although that failure actually helped Mylan's stock climb somewhat. Meanwhile, the company got caught up in the broader downturn in drug stocks caused by political pressure over prescription-drug pricing.

That's all in the past, though. After buying Mylan's stock, Einhorn said he thought the company's share buybacks and strong pipeline presented a great opportunity. He was right, in my view, especially about Mylan's pipeline. The biggest potential prize in that pipeline is the first generic version of Advair. Mylan also has 15 biosimilars in its pipeline of drugs that combined for sales of over $40 billion. 

So although Einhorn doesn't always pick winners, his buy of Mylan looks like a smart pick that over the long run will add significantly to his already large cash pile.

Invest Smarter with The Motley Fool

Join Over 1 Million Premium Members Receiving…

  • New Stock Picks Each Month
  • Detailed Analysis of Companies
  • Model Portfolios
  • Live Streaming During Market Hours
  • And Much More
Get Started Now

Stocks Mentioned

Merck & Co., Inc. Stock Quote
Merck & Co., Inc.
MRK
$93.55 (1.58%) $1.46
Keryx Biopharmaceuticals, Inc. Stock Quote
Keryx Biopharmaceuticals, Inc.
KERX
Viatris Inc. Stock Quote
Viatris Inc.
MYL

*Average returns of all recommendations since inception. Cost basis and return based on previous market day close.

Related Articles

Motley Fool Returns

Motley Fool Stock Advisor

Market-beating stocks from our award-winning service.

Stock Advisor Returns
331%
 
S&P 500 Returns
115%

Calculated by average return of all stock recommendations since inception of the Stock Advisor service in February of 2002. Returns as of 05/21/2022.

Discounted offers are only available to new members. Stock Advisor list price is $199 per year.

Premium Investing Services

Invest better with The Motley Fool. Get stock recommendations, portfolio guidance, and more from The Motley Fool's premium services.